TABLE 2.
n (%) | |
---|---|
Induction immunosuppression | |
None | 27 (31.8) |
IL-2 receptor antagonist | 14 (16.5) |
Antithymocyte globulin | 41 (48.2) |
Anti-CD52 (alemtuzumab) | 3 (3.5) |
Primary oral immunosuppressant | |
TAC/MMF/P | 64 (75.0) |
CsA/MMF/P | 7 (8.2) |
CsA/SRL/P | 2 (2.4) |
SRL/MMF/P | 2 (2.4) |
TAC/AZA/P | 2 (2.4) |
TAC/SRL/P | 1 (1.2) |
TAC/MMF | 4 (4.7) |
TAC/P | 2 (2.4) |
CsA/P | 1 (1.2) |
Follow-up (mean±SD, yr) | 5.4 (3.4) |
Acute rejection, n (%) | 13 (15.3) |
Polyomavirus (BK)-associated nephropathy | 6 (7.1) |
SCr at 1 yr post-KTX, median (range), mg/dL | 1.3 (0.8–2.4) |
Clinical relapse of AAV | |
Total group | 7/85 (8.2) |
WG group | 5/42 (11.9) |
MPA group | 2/39 (5.1) |
ANCA-positive at time of KTX | 4/29 (13.8) |
ANCA-negative at time of KTX | 1/46 (2.2) |
ANCA-unknown at time of KTX | 2/10 (20.0) |
AZA, azathioprine; CsA, cyclosporine; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; SRL, sirolimus; TAC, tacrolimus; WG, Wegener’s granulomatosis; ANCA, antineutrophil cytoplasmic antibody; KTX, kidney transplantation; IL, interleukin; AAV, ANCA-associated vasculitis.